We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
Trial findings revealed that the therapy effectively controlled symptoms such as runny nose and nasal itching. Credit: Pormezz/Shutterstock. China’s National Medical Products Administration (NMPA) has ...
Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...
Wide-moat GSK’s fourth-quarter earnings were in line ... to oncology drugs Jemperli and Blenrep and immunology candidates depemokimab (ultra-long-acting IL-5 inhibitor for asthma and chronic ...
This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...
including Blenrep for multiple myeloma and depemokimab for severe asthma. CEO Emma Walmsley emphasized prioritizing R&D in respiratory, oncology, and HIV treatments. For 2025, GSK expects turnover ...
plus over 4 billion pound sterling in combined peak sales from Nucala and the near-market long-acting IL-5 drug depemokimab, will help boost the contribution of GSK's specialty medicines portfolio ...
HL Building Blocks Build your own portfolio with HL's specially designed fund range Wealth Shortlist A selection of funds we've researched and chosen for their long-term potential ...
Strong full-year trading and an improving outlook have propelled GSK’s share price higher, as Royston Wild explains. The content of this article is provided for information purposes only and is ...
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results